XmAb23104

BIOLOGICAL2 trials

Sponsors

University of California, San Francisco, Memorial Sloan Kettering Cancer Center

Conditions

Advanced MelanomaMetastatic MelanomaSarcoma

Phase 1

XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy

TerminatedNCT05695898

University of California, San FranciscoAdvanced Melanoma, Metastatic Melanoma

Start: 2023-02-28End: 2024-04-29Updated: 2025-03-26

Phase 2

A Study of XmAb23104 in People With Sarcoma

TerminatedNCT05879185

Memorial Sloan Kettering Cancer CenterSarcoma

Start: 2023-04-06End: 2024-07-19Updated: 2026-04-13

Related Papers

775 Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint Inhibitor therapy with and without CNS disease

Regular and Young Investigator Award Abstracts2023-10-311 citations

Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease.

Journal of Clinical Oncology2023-06-0111 citations